Can daily vitamin C reduce mortality or complications in people with precancerous blood disorders?

Lens adapted to this topic: Promising supportive-treatment signal

A more optimistic reading emphasizes that correcting commonly low vitamin C levels may improve resilience or inflammatory regulation without shrinking abnormal clones. The EVITA findings of fewer adverse events and an exploratory survival advantage are consistent with a supportive-care effect rather than direct anticancer activity. This interpretation remains provisional because the key survival result was exploratory and needs replication.

• Restoring vitamin C levels may influence inflammatory signaling and other biological processes even when abnormal clone growth is unchanged.
• The trial reported fewer adverse events and a favorable survival signal among participants receiving 1,000 mg/day.
• The findings could indicate a supportive-care benefit rather than elimination or slowing of the abnormal blood-cell clones.
• The strongest case for this interpretation is that the intervention was randomized and placebo-controlled, while the main limitation is the need for phase 3 validation.

Featured sourcePhase 2 trial suggests vitamin C may benefit people with pre-cancer blood disorders – Van Andel Institutevai.org7 sourcesView sources